Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001957912-26-000007·Baselake Partners, LP
Schedule 13G ownership disclosure
NEUPHORIA THERAPEUTICS INC
Common Stock, $0.00001 par value per share · CUSIP: 64136E102
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Baselake Partners, LP
Shares: 222,222 · Class: 4.1%
- Baselake Management, LLC
Shares: 222,222 · Class: 4.1%
- David Paolella
Shares: 222,222 · Class: 4.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001957912-26-000007
- Form type
- SCHEDULE 13G/A
- Filer
- Baselake Partners, LP
- CIK
- CIK 1957912
- Filed
- Feb 06, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership